Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Moracin P (CAS No.: 102841-46-3) is a natural compound isolated from the root bark of mulberry trees (Mori Cortex Radicis) and belongs to the 2-aryl benzofuran class. In recent years, with the deepening of pharmacological research on natural products, Sanxin P has attracted widespread attention due to its remarkable biological activity. It demonstrates potential medicinal value in anti-tumor, neuroprotection, anti-inflammatory, and antioxidant properties, especially showing promising therapeutic prospects in models of ischemic stroke, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis. This article will systematically review the chemical structure, origin, and extraction method of Sanxin P in detail, elaborate on its pharmacological activity and mechanism of action, and explore its clinical application potential in conjunction with druggability evaluation, aiming to provide scientific support for further research and development of this compound.

Chemical structure and physicochemical properties

The molecular formula of Sansinul P is C20H18O5, with a molecular weight of 326.34. Its core structure is a 2-aryl benzofuran backbone, which contains multiple hydroxyl substituents, giving it certain polarity and hydrogen bond formation capabilities. In terms of physicochemical properties, the LogP value of Sancinol P is about 3.0, indicating moderate lipid solubility that facilitates cell membrane penetration. The topological pole surface area (TPSA) is 86.18 Ų, and the number of hydrogen bond acceptors is 5, indicating strong affinity for binding to biological macromolecules. Although its blood-brain barrier permeability (BBB score is relatively low), it still demonstrates significant biological activity in central nervous system disease models, suggesting it may exert effects through indirect mechanisms or local actions. Regarding safety indicators such as hepatotoxicity, cardiotoxicity, hERG channel inhibition, and genotoxicity (Ames test), systematic studies are currently lacking and require further evaluation.

Plant Origins and Extraction Methods

Mori Cortex Radicis P mainly comes from the root bark of mulberry trees (Mori Cortex radicis), a plant of the mulberry family, widely used in traditional Chinese medicine to treat various diseases. The extraction of Sanxin P typically uses organic solvent extraction combined with column chromatography separation technology. Specific methods include:

1. Raw material preparation: Select dried mulberry root bark and crush it into fine powder.
2. Solvent extraction: Multiple reflux extractions using ethanol or methanol to extract the active components.
3. Crude extract concentration: Removes solvent by vacuum concentration to obtain a concentrated crude extract.
4. Separation and purification: Separation is performed using silica gel column chromatography or reversed-phase high-performance liquid chromatography (RP-HPLC), combined with thin-layer chromatography (TLC) to monitor the purity of the target component.
5. Structural identification: The structure of sansinul P was confirmed using nuclear magnetic resonance (NMR), mass spectrometry (MS), and infrared spectroscopy (IR).

In recent years, with advances in chromatography technology and separation and purification methods, the extraction efficiency and purity of Sanxin P have significantly improved, providing a solid material foundation for its pharmacological research.

Pharmacological activity research

Sanxin P exhibits broad pharmacological activity across various disease models, mainly including anti-tumor, neuroprotective, anti-inflammatory, and antioxidant effects.

Antitumor activity

Sancinsin P exhibits inhibitory effects on various tumor cell lines, and related studies show it achieves anti-tumor effects by regulating multiple signaling pathways. Its main targets include anti-apoptotic proteins MCL1 and BCL2, signal transduction factor STAT3, as well as matrix metalloproteinase MMP2 and topoisomerases TOP1 and TOP2A. Sanxin P can inhibit tumor cell proliferation, induce apoptosis, block tumor cell migration and invasion, and demonstrate good anti-cancer potential.

Neuroprotective effects

In the ischemic stroke model, sancinol P significantly reduced neuronal damage by inhibiting hypoxia-inducible factor-1α (HIF1A) and reducing the production of reactive oxygen species (ROS) induced by oxygen glucose deprivation (OGD). Additionally, Sancinol P regulates key factors such as NADPH oxidase (NOX2), nuclear factor κB (NFKB1), and glutamate receptor (GRIN1), exerting antioxidant and anti-inflammatory effects to protect neurons from ischemia-reperfusion injury.

Anti-inflammatory effects

Sanxin P demonstrates good anti-inflammatory activity in inflammatory diseases such as rheumatoid arthritis. By inhibiting the signaling pathways of tumor necrosis factor α (TNF), interleukin-1β (IL1B), cyclooxygenase-2 (PTGS2), and nuclear factor κB (NFKB1), it reduces the production and release of inflammatory mediators and alleviates tissue inflammatory responses. Additionally, Sanxin P can reduce the generation of reactive oxygen species and alleviate inflammatory damage related to oxidative stress.

Potential effects of other neurodegenerative diseases

In models related to Alzheimer's and Parkinson's disease, Sancinsul P regulates key targets such as β-amyloid precursor protein (APP), Tau protein (MAPT), α-synuclein (SNCA), and superoxide dismutase (SOD1, SOD2), thereby regulating abnormal protein deposition and oxidative stress within neurons, reducing neuroinflammation, and delaying the progression of neurodegenerative diseases.

Mechanism of action and molecular targets

The multi-target mechanism of Sanxin P forms the basis of its broad pharmacological activity. Its main mechanisms of action include:

1. Regulates hypoxia-inducible factor (HIF-1) signaling pathways
   Sansinin P significantly inhibits the expression and activity of HIF-1α, blocks cellular adaptive responses under hypoxic conditions, reduces pro-angiogenesis and metabolic reprogramming, and exerts antitumor and neuroprotective effects.

2. Inhibits reactive oxygen species (ROS) production and oxidative stress
   By reducing NADPH oxidase (NOX2) activity, Sancinol P lowers ROS levels, protects cells from oxidative damage, and alleviates inflammatory responses.

3. Regulates apoptosis-related proteins
   Sancinin P downregulates anti-apoptotic proteins MCL1 and BCL2, promoting tumor cell apoptosis. At the same time, it inhibits the STAT3 signaling pathway, blocking cell proliferation and survival signals.

4. Intervention of anti-inflammatory signaling pathways
   By inhibiting nuclear factor κB (NFKB1) activity, Trixin P reduces the expression of pro-inflammatory cytokines (TNF, IL1B) and inflammatory enzymes (PTGS2), thereby alleviating inflammatory responses.

5. Neurotransmitter and receptor regulation
   Sancinin P affects the functions of glutamate receptors (GRIN1, GRIN2B) and dopamine receptor D2 (DRD2), regulates nerve signal transmission, and improves neurological dysfunction.

6. regulation of abnormal protein aggregation
   In neurodegenerative diseases, Sancintin P regulates APP, Tau protein, and α-synuclein proteins, reducing abnormal protein deposition and protecting neuronal structural integrity.

In summary, Sanxin P leverages its diverse pharmacological effects through multi-target and multi-pathway synergistic effects, reflecting the complex bioactivity characteristics of natural products.

Druggability evaluation and pharmacokinetics

The druggability parameters of Sanxin Su P indicate that it has certain potential for drug development. The molecular weight of 326.34 falls within the ideal range of Lipinski's rule, with a LogP of 3.0, indicating moderate lipid solubility and favorable oral absorption. TPSA is 86.18 Ų, with 5 hydrogen bond receptors, indicating good membrane permeability and binding ability in organisms.

However, the low blood-brain barrier permeability of sanxinsul P limits its ability to act directly on the central nervous system, which may affect its application in neurological diseases. In the future, structural modification or carrier systems will be needed to improve brain bioavailability.

Currently, systematic in vivo pharmacokinetic data, including absorption, distribution, metabolism, and excretion (ADME) characteristics, is still lacking. For safety evaluation, indicators such as hepatotoxicity, cardiotoxicity (hERG channel inhibition), and genotoxicity (Ames test) remain unclear, requiring related toxicological studies.

In addition, the metabolic pathway of sancinol P and the activity of its metabolites are also worth in-depth exploration to assess its in vivo stability and potential duration of efficacy.

Prospects and outlooks for clinical applications

With its multi-target and multi-mechanism pharmacological activity, Sanxin P demonstrates broad clinical application prospects. Its potential in the anti-tumor field is particularly prominent, and in the future, it could serve as a new candidate for chemotherapy adjuvant drugs or targeted therapies. Its neuroprotective and anti-inflammatory effects make it valuable for developing neurodegenerative diseases such as ischemic stroke, Alzheimer's disease, and Parkinson's disease.

For inflammatory diseases such as rheumatoid arthritis, the anti-inflammatory activity of Sancinsu P provides a theoretical basis for its role as a novel anti-inflammatory drug. In the future, combining modern drug delivery technologies, such as nanocarriers and liposomes, is expected to improve bioavailability and targeting, enhancing therapeutic outcomes.

However, the clinical translation of Sanxin Su P still faces many challenges, including unclear pharmacokinetic characteristics, lack of safety data, and insufficient blood-brain barrier permeability. Future research should focus on:

• Structural optimization to improve pharmacokinetics and brain permeability;
• Systematic toxicological assessment to ensure safety;
• In-depth validation of in vivo disease models to clarify treatment windows and dosages;
• Exploring combination medication strategies to leverage synergistic effects.

Overall, Sanxin P, as a natural product with multiple pharmacological activities, has important potential to become a novel drug and deserves further systematic research and clinical development.

Conclusion

Sansinin P, a 2-aryl benzofuran natural product isolated from mulberry root bark, has become a hot topic in pharmacological research of natural products due to its unique chemical structure and diverse biological activities. Its multi-target mechanisms in anti-tumor, neuroprotection, anti-inflammatory, and antioxidant effects provide new ideas for the treatment of complex diseases. Although its druggability and safety still require further systematic evaluation, Sancinsol P is undoubtedly a natural drug lead compound with great development potential. In the future, combining modern research in medicinal chemistry, pharmacology, and pharmacokinetics, it is expected to promote the translation of Sanxin P into clinical applications, benefiting a wide range of patients.